Chronic Kidney Disease Market: Epidemiology, Therapies, Companies, DelveInsight | ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Phar

Chronic Kidney Disease therapies, such as Ocedurenone (KBP-5074), BI 690517 + Empagliflozin, and others, are expected to boost the Chronic Kidney Disease Market in the upcoming years.

DelveInsight has launched a new report on "Chronic Kidney Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Chronic Kidney Disease market report @ https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Chronic Kidney Disease Market Report:

In 2023, the Chronic Kidney Disease therapeutics market in the United States was valued at approximately USD 2,824 million, with projections indicating further growth throughout the forecast period.
The U.S. also recorded the highest prevalence of CKD among the 7MM, with around 40 million cases, a number expected to rise by 2034. That year, CKD affected roughly 2 million men and 3 million women in the U.S.
The current CKD treatment landscape includes erythropoietin-stimulating agents (ESAs), ACE inhibitors and ARBs, antidiabetic drugs, secondary hyperparathyroidism (SHPT) therapies, and urate-lowering treatments. Collectively, these accounted for a market size of USD 5,479 million across the 7MM in 2023. This figure is projected to increase with the anticipated arrival of novel therapies between 2024 and 2034.
In March 2023, Boehringer Ingelheim announced encouraging Phase II trial results for BI 690517, a selective aldosterone synthase inhibitor. When added to empagliflozin (an SGLT2 inhibitor), BI 690517 led to a reduction in albuminuria of up to 39.5%, compared to placebo. This was the first trial to evaluate this novel class alongside standard-of-care therapy, and the results were highlighted at the American Society of Nephrology's Kidney Week 2023.
According to DelveInsight's analysis, the estimated number of diagnosed prevalent cases of Chronic Kidney Disease across the 7 major markets (7MM) was approximately 16 million in 2023.
The United States reported the highest number of diagnosed cases, with around 5 million, and this figure is anticipated to increase in the coming years.
In Japan, the CKD market reached USD 1,402 million in 2023 and is projected to grow significantly through 2034.
In March 2025, the FDA broadened the approval of Furoscix (furosemide injection) to include the treatment of edema in adults with chronic kidney disease (CKD), including those with nephrotic syndrome. The expanded indication, developed by scPharmaceuticals, Inc., is expected to become available by April 2025, following the agency's acceptance of the supplemental new drug application in July 2024.
In January 2025, the FDA approved a new indication for semaglutide, allowing its use to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD, as announced by Novo Nordisk.
Key Chronic Kidney Disease companies such as ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc, Lexicon Pharmaceuticals, Sanofi, and others are evaluating new drugs for Chronic Kidney Disease to improve the treatment landscape.
Promising Chronic Kidney Disease therapies include ONC 201, DSP-7888, AV-GBM-1, DB102, AB-218, and others.

Chronic Kidney Disease Overview

Chronic Kidney Disease (CKD) is a progressive, long-lasting condition marked by the gradual decline of kidney function. It is most often linked to underlying conditions such as diabetes and high blood pressure, which can harm the kidneys' blood vessels. Common symptoms include fatigue, swelling (edema), and altered urination patterns. CKD advances through five stages, ranging from mild impairment in stage 1 to complete kidney failure, or end-stage renal disease (ESRD), in stage 5. Timely diagnosis through blood and urine tests is essential for effective disease management and slowing its progression.

Chronic Kidney Disease Market Outlook

Chronic Kidney Disease management centers on slowing its progression, alleviating symptoms, and minimizing complications. Key to treatment are lifestyle changes, such as adopting a kidney-friendly diet, engaging in regular physical activity, and quitting smoking. Patients are typically encouraged to limit salt, potassium, and protein intake to ease the burden on the kidneys.

Medications play a vital role in CKD care. ACE inhibitors and angiotensin II receptor blockers (ARBs) are frequently prescribed to manage high blood pressure and reduce protein in the urine, both of which can slow disease advancement. Statins help address high cholesterol levels and reduce cardiovascular risk, which is elevated in CKD patients.

For those with diabetes-related CKD, maintaining blood sugar levels is crucial. Treatments may include drugs like metformin and SGLT2 inhibitors, which offer protective benefits for the kidneys. Anemia, a common issue in CKD, is often managed using erythropoiesis-stimulating agents (ESAs) and iron supplementation.

In later stages of CKD, when kidney function is severely compromised, renal replacement therapies become necessary. These include hemodialysis and peritoneal dialysis, which take over the kidney's filtering role. For patients with end-stage renal disease (ESRD), a kidney transplant is the most effective treatment, although it requires ongoing use of immunosuppressants to avoid organ rejection.

Overall, effective CKD treatment also involves targeting root causes-such as hypertension, high blood sugar, and elevated cholesterol-while ensuring regular health monitoring and timely therapeutic adjustments to enhance patient outcomes and quality of life.

Discover how the Chronic Kidney Disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Kidney Disease Marketed Drugs
KERENDIA (finerenone): Bayer HealthCare Pharmaceuticals Inc.
INVOKANA (canagliflozin): Janssen Research & Development, LLC

Chronic Kidney Disease Emerging Drugs

Ocedurenone (KBP-5074): KBP Biosciences
BI 690517 + Empagliflozin

Scope of the Chronic Kidney Disease Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Chronic Kidney Disease Companies: ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc., Lexicon Pharmaceuticals, Sanofi, and others
Chronic Kidney Disease Therapies: Ocedurenone (KBP-5074), BI 690517 + Empagliflozin, and others.
Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and Chronic Kidney Disease emerging therapies
Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Chronic Kidney Disease Unmet Needs, KOL's views, Analyst's views, Chronic Kidney Disease Market Access and Reimbursement

To know what's more in our Chronic Kidney Disease report, visit https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Chronic Kidney Disease Market Report:
Chronic Kidney Disease market report covers a descriptive overview and comprehensive insight of the Chronic Kidney Disease Epidemiology and Chronic Kidney Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Chronic Kidney Disease market report provides insights into the current and emerging therapies.
The Chronic Kidney Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Chronic Kidney Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Kidney Disease market.

Got queries? Click here to know more about the Chronic Kidney Disease market Landscape https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Chronic Kidney Disease Patient Share (%) Overview at a Glance
5. Chronic Kidney Disease Market Overview at a Glance
6. Chronic Kidney Disease Disease Background and Overview
7. Chronic Kidney Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Kidney Disease
9. Chronic Kidney Disease Current Treatment and Medical Practices
10. Unmet Needs
11. Chronic Kidney Disease Emerging Therapies
12. Chronic Kidney Disease Market Outlook
13. Country-Wise Chronic Kidney Disease Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Chronic Kidney Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Chronic Kidney Disease Market Outlook 2034 https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Chronic Kidney Disease Pipeline Insights, DelveInsight

"Chronic Kidney Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Kidney Disease market. A detailed picture of the Chronic Kidney Disease pipeline landscape is provided, which includes the disease overview and Chronic Kidney Disease treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.